Investigational drug · Phase 3
Test drug CB03-154 group
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for ALS (Amyotrophic Lateral Sclerosis), Focal Epilepsy.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "Test drug CB03-154 group"
First trial start
2024
Aug 14, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Test drug CB03-154 group", any sponsor or status.
Conditions studied
As listed on its trial records.
- ALS (Amyotrophic Lateral Sclerosis)
- Focal Epilepsy
Approved drugs for the same conditions: Epilepsy and seizures · ALS (amyotrophic lateral sclerosis) · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Test drug CB03-154 group" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)Pivotal-lookingRecruiting
Shanghai Zhimeng Biopharma, Inc.Industry
NCT07082192 · 240 participants (planned) · Start Oct 30, 2025 · Primary completion Sep 30, 2027
Drug: Test drug CB03-154 5mg group; Test drug CB03-154 10mg group and 2 more · For: ALS (Amyotrophic Lateral Sclerosis)
Sites: Beijing, China
- A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal EpilepsyPivotal-lookingRecruiting
Shanghai Zhimeng Biopharma, Inc.Industry
NCT06612775 · 180 participants (planned) · Start Aug 14, 2024 · Primary completion Sep 2027
Drug: Test drug CB03-154 5mg group; Test drug CB03-154 10mg group and 2 more · For: Focal Epilepsy
Sites: Melbourne, Australia
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for ALS (Amyotrophic Lateral Sclerosis)
- Foralumab NasalPhase 22 trials
Tiziana Life Sciences LTD · ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis, ALS
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.